Passifs Courants Changement Date
Alnylam Pharmaceuticals USD 1.35B 116.87M 2026-03
BioCryst Pharmaceuticals USD 196.07M 5.83M 2025-12
Chugai Pharma JPY 327.7B 83.38B 2026-03
Daiichi Sankyo JPY 778.55B 77.51B 2025-12
DBV Technologies USD 58.02M 8.54M 2025-12
Enanta Pharmaceuticals USD 44.73M 3.83M 2025-12
Gilead Sciences USD 11.81B 485M 2025-12
GlaxoSmithKline GBP 22.43B 1.04B 2026-03
Glaxosmithkline GBP 28.82B 144.79M 2025-12
Incyte USD 1.49B 25.52M 2026-03
Ionis Pharmaceuticals USD 717M 66M 2026-03
Karyopharm Therapeutics USD 92.06M 4.9M 2025-12
Neurocrine Biosciences USD 831.7M 88.3M 2026-03
Novavax USD 342.46M 117.49M 2026-03
PTC Therapeutics USD 968.43M 102.18M 2025-12
Regeneron Pharmaceuticals USD 5.11B 739.3M 2026-03
Roche Holding CHF 28B 421M 2025-12
Sarepta Therapeutics USD 1.1B 173.86M 2025-12
Ultragenyx Pharmaceutical USD 325M 59M 2026-03
Vertex Pharmaceuticals USD 3.88B 19.4M 2026-03